Pfizer Inc.
$27.72
The Read: Pfizer's stock rallied on strong Q4 2025 earnings and operational growth, dipped slightly on neutral Q1 2026 results but found support from positive trial data and patent extensions, held steady amid mixed oncology updates, fell below the bear floor on Q2 earnings but rebounded sharply on cost realignment and bullish clinical strategy updates.
PFE
Hover to view data
No Data